U.S. Markets close in 2 hrs 29 mins

Astria Therapeutics, Inc. (ATXS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
13.06+0.42 (+3.36%)
As of 01:31PM EDT. Market open.

Astria Therapeutics, Inc.

100 High Street
28th Floor
Boston, MA 02110
United States
617 349 1971

Full Time Employees29

Key Executives

NameTitlePayExercisedYear Born
Ms. Jill C. Milne Ph.D.Co-Founder, CEO, Pres & Director837.45kN/A1968
Mr. Noah Clauser CPAChief Financial Officer508.79kN/A1974
Dr. Andrew J. Nichols Ph.D.Chief Scientific Officer580.45kN/A1961
Mr. Benjamin S. Harshbarger J.D.Chief Legal OfficerN/AN/A1969
Ms. Keri McGrailSr. VP of HRN/AN/AN/A
Ms. Andrea L. MatthewsSr. VP of Corp. AffairsN/AN/AN/A
Mr. Andrew A. KomjathyChief Commercial OfficerN/AN/A1964
Dr. Anthony Christopher Stevens M.D.Interim Chief Medical OfficerN/AN/A1959
Dr. Christopher J. Morabito M.D.Chief Medical OfficerN/AN/A1970
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Corporate Governance

Astria Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.